News | November 06, 2024
Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Silica is a proven and highly effective anti-caking agent that has been used for decades
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Subscribe To Our Newsletter & Stay Updated
